436088-75-4 Usage
Uses
Used in Pharmaceutical Synthesis:
5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID is used as an intermediate in the synthesis of various pharmaceuticals for its potential therapeutic applications. Its unique structure allows for the development of new drugs with specific targeting and efficacy profiles.
Used in Agrochemical Development:
In the agrochemical industry, 5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID is used as a key component in the creation of new agrochemicals, contributing to the development of more effective and targeted pest control solutions.
Used in Organic Synthesis:
As a building block in organic synthesis, 5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID is employed for the construction of complex organic molecules, facilitating advancements in chemical research and the discovery of novel compounds with diverse applications.
Used in Drug Discovery:
5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID is utilized in drug discovery processes to explore its potential as a lead compound for the development of new therapeutic agents, particularly in the areas of medicinal chemistry and biochemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 436088-75-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,6,0,8 and 8 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 436088-75:
(8*4)+(7*3)+(6*6)+(5*0)+(4*8)+(3*8)+(2*7)+(1*5)=164
164 % 10 = 4
So 436088-75-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H8N4O3/c15-9(14-6-3-1-2-4-11-6)7-8(10(16)17)13-5-12-7/h1-5H,(H,12,13)(H,16,17)(H,11,14,15)/p-1
436088-75-4Relevant academic research and scientific papers
Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase-LEDGF/p75 interaction
Serrao, Erik,Xu, Zhong-Liang,Debnath, Bikash,Christ, Frauke,Debyser, Zeger,Long, Ya-Qiu,Neamati, Nouri
, p. 5963 - 5972 (2013/09/23)
Though much progress has been made in the inhibition of HIV-1 integrase catalysis, clinical resistance mutations have limited the promise of long-term drug prescription. Consequently, allosteric inhibition of integrase activity has emerged as a promising approach to antiretroviral discovery and development. Specifically, inhibitors of the interaction between HIV-1 integrase and cellular cofactor LEDGF/p75 have been validated to diminish proviral integration in cells and deliver a potent reduction in viral replicative capacity. Here, we have contributed to the development of novel allosteric integrase inhibitors with a high-throughput AlphaScreen-based random screening approach, with which we have identified novel 5-carbonyl-1H-imidazole-4-carboxamides capable of inhibiting the HIV-1 integrase-LEDGF/p75 interaction in vitro. Following a structure-activity relationship analysis of the initial 1H-imidazole-4,5- dicarbonyl core, we optimized the compound's structure through an industrial database search, and we went further to synthesize a selective and non-cytotoxic panel of inhibitors with enhanced potency.
